Yesterday it was reported that a Director at CareDx (CDNA), George Bickerstaff, exercised options to buy 4,415 CDNA shares at $1.12 a share, for a total transaction value of $4,944.
This recent transaction increases George Bickerstaff’s holding in the company by 5.08% to a total of $2.42 million.
See today’s analyst top recommended stocks >>
Based on CareDx’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $23.51 million and GAAP net loss of $3.76 million. In comparison, last year the company earned revenue of $14.05 million and had a GAAP net loss of $8.97 million. Currently, CareDx has an average volume of 962.4K. The Company has a Price to Book ratio of 11.4153.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $38.25, reflecting a 44.6% upside. Three different firms, including Jefferies and Piper Jaffray, currently also have a Buy rating on the stock.
The insider sentiment on CareDx has been neutral according to 76 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
